SI20816A - Polimorfi torsemid-a - Google Patents

Polimorfi torsemid-a Download PDF

Info

Publication number
SI20816A
SI20816A SI200020037A SI200020037A SI20816A SI 20816 A SI20816 A SI 20816A SI 200020037 A SI200020037 A SI 200020037A SI 200020037 A SI200020037 A SI 200020037A SI 20816 A SI20816 A SI 20816A
Authority
SI
Slovenia
Prior art keywords
torsemide
modification
solvent
mixture
preparation
Prior art date
Application number
SI200020037A
Other languages
English (en)
Slovenian (sl)
Inventor
Judith Aronhime
David Leonov
Marko Kordova
Anchel Schwartz
Ben-Zion Dolitzky
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of SI20816A publication Critical patent/SI20816A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
SI200020037A 1999-08-11 2000-08-11 Polimorfi torsemid-a SI20816A (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30
PCT/US2000/022081 WO2001010441A1 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Publications (1)

Publication Number Publication Date
SI20816A true SI20816A (sl) 2002-08-31

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200020037A SI20816A (sl) 1999-08-11 2000-08-11 Polimorfi torsemid-a

Country Status (24)

Country Link
US (1) US6465496B1 (hr)
EP (1) EP1207880A4 (hr)
JP (1) JP2003527319A (hr)
KR (1) KR20020025217A (hr)
CN (1) CN1378448A (hr)
AU (1) AU781461C (hr)
BG (1) BG106400A (hr)
CA (1) CA2379322A1 (hr)
CZ (1) CZ2002404A3 (hr)
DE (1) DE00957398T1 (hr)
ES (1) ES2204354T1 (hr)
HK (1) HK1046636A1 (hr)
HR (1) HRP20020120A2 (hr)
HU (1) HUP0204318A3 (hr)
IL (1) IL148031A0 (hr)
LT (1) LT5004B (hr)
MX (1) MXPA02001369A (hr)
NO (1) NO20020622L (hr)
PL (1) PL354262A1 (hr)
SI (1) SI20816A (hr)
SK (1) SK1912002A3 (hr)
TR (1) TR200200353T2 (hr)
WO (1) WO2001010441A1 (hr)
YU (1) YU9502A (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2410802A1 (en) * 2000-02-17 2002-09-06 Minutza Leibovici A stable pharmaceutical formulation comprising torsemide modification ii
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (hr) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (hr) * 2002-07-19 2008-11-30 Pliva D.D. Novi postupak za pripravu modifikacije i n-(1-metiletilaminokarbonil)-4-(3-metilfenilamino)-3-piridinsulfonamida
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
US30633A (en) 1860-11-13 Improvement in fire-escapes
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
DE3529529A1 (de) 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
WO2001070226A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
LT2002017A (en) 2002-11-25
YU9502A (sh) 2005-06-10
HK1046636A1 (zh) 2003-01-24
AU6902600A (en) 2001-03-05
BG106400A (en) 2002-08-30
IL148031A0 (en) 2002-09-12
CZ2002404A3 (cs) 2002-06-12
NO20020622D0 (no) 2002-02-08
HUP0204318A3 (en) 2005-03-29
KR20020025217A (ko) 2002-04-03
CN1378448A (zh) 2002-11-06
LT5004B (lt) 2003-03-25
EP1207880A1 (en) 2002-05-29
HUP0204318A2 (en) 2003-05-28
WO2001010441A1 (en) 2001-02-15
AU781461B2 (en) 2005-05-26
MXPA02001369A (es) 2005-08-26
TR200200353T2 (tr) 2002-06-21
SK1912002A3 (en) 2002-07-02
PL354262A1 (en) 2003-12-29
ES2204354T1 (es) 2004-05-01
DE00957398T1 (de) 2004-04-15
JP2003527319A (ja) 2003-09-16
HRP20020120A2 (en) 2003-10-31
EP1207880A4 (en) 2004-09-01
CA2379322A1 (en) 2001-02-15
NO20020622L (no) 2002-03-14
AU781461C (en) 2006-02-23
US6465496B1 (en) 2002-10-15

Similar Documents

Publication Publication Date Title
SI20816A (sl) Polimorfi torsemid-a
WO2002000216A1 (en) Carvedilol
EP2710015B1 (en) Polymorph of rifaximin and process for the preparation thereof
EP2000141A1 (en) Methods for preparing crystalline quetiapine hemifumarate
MX2007007301A (es) Polimorfos de clorhidrato de memantina.
WO2006012385A2 (en) Crystalline mycophenolate sodium
CZ289730B6 (cs) Krystalický hydrochlorid (R)-(-)-2-{N-[4-(1,1-dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-budyl]-aminomethyl}-chromanu, způsob jeho výroby, farmaceutický prostředek tuto látku obsahující a její pouľití
US20040214858A1 (en) Zolpidem hemitartrate
JP2007514000A (ja) テガセロッド塩基及びその塩の多形現象形
US20080027223A1 (en) Polymorphs of eszopiclone malate
EP1507531B1 (en) Stable pharmaceutical compositions of desloratadine
EP1468997A2 (en) Polymorphous forms of rosiglitazone maleate
US10941116B2 (en) Crystalline forms of mesaconine and preparation methods therefor
US20070260068A1 (en) Method for the Preparation of Crystal Forms of Torsemide in a Pure State
KR19980064286A (ko) 다형태를 갖는 독사조신 메실레이트의 새로운 형태(제 1형)
KR100336247B1 (ko) 7-[7-(s)-아미노-5-아자스피로[2,4]헵탄-5-일]-8-클로로-6-플루오로-1-[(1r,2s)-2-플루오로사이클로프로필]-4-옥소-1,4-디하이드로퀴놀린-3-카복실산의무수물,및이의3/2수화물의선택적수득방법
RU2220137C2 (ru) Термодинамически устойчивая форма (r)-3-[[(4-фторфенил)-сульфонил]амино]-1,2,3,4-тетрагидро-9н-карбазол-9-пр опановой кислоты (раматробана)
US6133269A (en) Polymorphic form of doxazosin mesylate (form II)
EP1598347A1 (en) Polymorphs of pantoprazole sodium salt and process for the preparation thereof
CZ284937B6 (cs) Zlepšená metoda syntézy 6,9-bis[(2-aminoetyl)amino] benzo [g]isochinolin-5,10-dion a jeho dimaleátové soli
CN114539135B (zh) 一种左旋氨氯地平的新盐型及其制备方法和应用
SI21616A (sl) Nove kristalne oblike karvedilola
ZA200200967B (en) Tomsemide Polymorphs.
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
CN112533894A (zh) 4,5-二羟基-2-(4-甲基苄基)异邻苯二甲腈溶剂化物及其结晶形式

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20080327